Stéphane Saubadu

444 total citations
11 papers, 231 citations indexed

About

Stéphane Saubadu is a scholar working on Pathology and Forensic Medicine, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Stéphane Saubadu has authored 11 papers receiving a total of 231 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pathology and Forensic Medicine, 3 papers in Endocrinology, Diabetes and Metabolism and 2 papers in Molecular Biology. Recurrent topics in Stéphane Saubadu's work include Multiple Sclerosis Research Studies (3 papers), Diabetes Treatment and Management (3 papers) and Oral and gingival health research (2 papers). Stéphane Saubadu is often cited by papers focused on Multiple Sclerosis Research Studies (3 papers), Diabetes Treatment and Management (3 papers) and Oral and gingival health research (2 papers). Stéphane Saubadu collaborates with scholars based in France, United States and Spain. Stéphane Saubadu's co-authors include Ronnie Aronson, Bo Åhrén, P. Miossec, Philippe Truffinet, Patrick Vermersch, Yang Mao‐Draayer, Erik Wallstroem, Raphaël Bejuit, Gavin Giovannoni and Biljana Djukic and has published in prestigious journals such as New England Journal of Medicine, Neurology and Diabetes Care.

In The Last Decade

Stéphane Saubadu

11 papers receiving 225 citations

Peers

Stéphane Saubadu
Tetsuro Arimura Japan
Genlong Xue China
Bimin Shi China
B Hehmke Germany
Hiroyuki Konya Japan
L.B. Bäcklund Sweden
Shijun Huang United States
P. Uitterlinden Netherlands
Guoqing Jiao China
Cathy K.Y. Shum Hong Kong
Tetsuro Arimura Japan
Stéphane Saubadu
Citations per year, relative to Stéphane Saubadu Stéphane Saubadu (= 1×) peers Tetsuro Arimura

Countries citing papers authored by Stéphane Saubadu

Since Specialization
Citations

This map shows the geographic impact of Stéphane Saubadu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Saubadu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Saubadu more than expected).

Fields of papers citing papers by Stéphane Saubadu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Saubadu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Saubadu. The network helps show where Stéphane Saubadu may publish in the future.

Co-authorship network of co-authors of Stéphane Saubadu

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Saubadu. A scholar is included among the top collaborators of Stéphane Saubadu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Saubadu. Stéphane Saubadu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Vermersch, Patrick, Cristina Granziera, Yang Mao‐Draayer, et al.. (2024). Inhibition of CD40L with Frexalimab in Multiple Sclerosis. New England Journal of Medicine. 390(7). 589–600. 34 indexed citations
2.
Giovannoni, Gavin, Cristina Granziera, Yang Mao‐Draayer, et al.. (2024). 151. Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-month Results from the Phase 2 Open-Label Extension. Multiple Sclerosis and Related Disorders. 92. 106112–106112. 1 indexed citations
3.
Krieger, Stephen, Patrick Vermersch, Tanuja Chitnis, et al.. (2024). 150. Frexalimab in Relapsing Multiple Sclerosis and Non-Relapsing Secondary Progressive Multiple Sclerosis: Design of Phase 3 Frexalt and Freviva Trials. Multiple Sclerosis and Related Disorders. 92. 106111–106111. 2 indexed citations
4.
Chitnis, Tanuja, Brenda Banwell, Ludwig Kappos, et al.. (2024). Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS. Multiple Sclerosis Journal. 30(7). 833–842. 6 indexed citations
5.
Kühle, Jens, Tanuja Chitnis, Brenda Banwell, et al.. (2023). Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial. Multiple Sclerosis Journal. 29(3). 385–394. 9 indexed citations
6.
Fischer, Tanya, Thomas Gasser, Stuart Isaacson, et al.. (2019). Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson’s disease patients with a GBA mutation (S4.002). Neurology. 92(15_supplement). 3 indexed citations
7.
Peterschmitt, Michel, Thomas Gasser, Stuart Isaacson, et al.. (2019). Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a GBA mutation. Molecular Genetics and Metabolism. 126(2). S117–S117. 15 indexed citations
8.
Henry, P., Bertrand Cariou, Maurizio Averna, et al.. (2018). Open-label ODYSSEY APPRISE study: Interim data from the first 843 participants. Archives of Cardiovascular Diseases Supplements. 10(1). 127–127. 1 indexed citations
9.
10.
Böhler, Steffen, et al.. (2011). Betaxolol versus Carvedilol in Chronic Heart Failure (BETACAR Study). Arzneimittelforschung. 49(4). 311–317. 2 indexed citations
11.
Saubadu, Stéphane, et al.. (1990). [A survey of self medication. Comparison of results obtained at two centers].. PubMed. 45(4). 325–9. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tetsuro Arimura Breakdown of academic impact, for papers by Genlong Xue Breakdown of academic impact, for papers by Bimin Shi Breakdown of academic impact, for papers by B Hehmke Breakdown of academic impact, for papers by Hiroyuki Konya Breakdown of academic impact, for papers by L.B. Bäcklund Breakdown of academic impact, for papers by Shijun Huang Breakdown of academic impact, for papers by P. Uitterlinden Breakdown of academic impact, for papers by Guoqing Jiao Breakdown of academic impact, for papers by Cathy K.Y. Shum
Rankless by CCL
2026